Zhejiang Xinguang Pharmaceutical Co Ltd (300519) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.006x

Based on the latest financial reports, Zhejiang Xinguang Pharmaceutical Co Ltd (300519) has a cash flow conversion efficiency ratio of -0.006x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-5.00 Million ≈ $-731.38K USD) by net assets (CN¥814.66 Million ≈ $119.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300519 net asset quality score to measure how much of total assets are equity-financed.

Zhejiang Xinguang Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Zhejiang Xinguang Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 300519 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Zhejiang Xinguang Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zhejiang Xinguang Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Yuen Foong Yu Consumer Prod
TW:6790
0.071x
Jiangsu Liance Electromechanical Technology Co. Ltd. A
SHG:688113
0.026x
Sophia Genetics SA
NASDAQ:SOPH
-0.145x
New Providence Acquisition Corp. III Class A Ordinary Shares
NASDAQ:NPAC
-0.001x
Teqnion AB
ST:TEQ
0.024x
Shanxi Huayang New Material Co Ltd
SHG:600281
-0.449x
PI Advanced Materials Co. Ltd
KQ:178920
0.051x
NanJing Sanchao Advanced Materials Co Ltd
SHE:300554
-0.017x

Annual Cash Flow Conversion Efficiency for Zhejiang Xinguang Pharmaceutical Co Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of Zhejiang Xinguang Pharmaceutical Co Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Zhejiang Xinguang Pharmaceutical Co Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥830.53 Million
≈ $121.53 Million
CN¥53.43 Million
≈ $7.82 Million
0.064x +1.91%
2023-12-31 CN¥844.12 Million
≈ $123.52 Million
CN¥53.29 Million
≈ $7.80 Million
0.063x -57.11%
2022-12-31 CN¥858.89 Million
≈ $125.68 Million
CN¥126.43 Million
≈ $18.50 Million
0.147x -12.50%
2021-12-31 CN¥846.22 Million
≈ $123.83 Million
CN¥142.36 Million
≈ $20.83 Million
0.168x +23.53%
2020-12-31 CN¥826.94 Million
≈ $121.01 Million
CN¥112.61 Million
≈ $16.48 Million
0.136x +10.82%
2019-12-31 CN¥799.71 Million
≈ $117.02 Million
CN¥98.27 Million
≈ $14.38 Million
0.123x -0.23%
2018-12-31 CN¥753.26 Million
≈ $110.23 Million
CN¥92.77 Million
≈ $13.58 Million
0.123x -30.03%
2017-12-31 CN¥705.81 Million
≈ $103.28 Million
CN¥124.23 Million
≈ $18.18 Million
0.176x -6.98%
2016-12-31 CN¥640.46 Million
≈ $93.72 Million
CN¥121.18 Million
≈ $17.73 Million
0.189x -53.11%
2015-12-31 CN¥309.35 Million
≈ $45.27 Million
CN¥124.84 Million
≈ $18.27 Million
0.404x +0.67%
2014-12-31 CN¥249.00 Million
≈ $36.44 Million
CN¥99.82 Million
≈ $14.61 Million
0.401x +40.78%
2013-12-31 CN¥201.97 Million
≈ $29.55 Million
CN¥57.51 Million
≈ $8.42 Million
0.285x -25.23%
2012-12-31 CN¥141.62 Million
≈ $20.72 Million
CN¥53.93 Million
≈ $7.89 Million
0.381x +15.50%
2011-12-31 CN¥104.32 Million
≈ $15.27 Million
CN¥34.40 Million
≈ $5.03 Million
0.330x --

About Zhejiang Xinguang Pharmaceutical Co Ltd

SHE:300519 China Drug Manufacturers - Specialty & Generic
Market Cap
$321.46 Million
CN¥2.20 Billion CNY
Market Cap Rank
#14384 Global
#4270 in China
Share Price
CN¥13.73
Change (1 day)
+1.85%
52-Week Range
CN¥11.85 - CN¥18.43
All Time High
CN¥52.02
About

Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health food in China. It offers pharmaceutical products that cover respiratory, digestive, and urinary systems, as well as cardiovascular, cerebrovascular, trauma, and pediatric diseases. The company was incorporated in 1998 and is headquar… Read more